Apremilast Viatris (apremilast)
- Region
- 🇪🇺 EU
- Active substance
- apremilast
- Company
- Viatris Limited
- Status
- Application withdrawn
- Therapeutic area
- Arthritis, Psoriatic; Psoriasis; Behcet Syndrome
- Application
- EMEA/H/C/006193
- ATC
- L04AA32
- Official record
- www.ema.europa.eu
Indication
Treatment of psoriatic arthritis, psoriasis, Behçet’s disease.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Apremilast Accord Authorised · Accord Healthcare S.L.U.
- 🇪🇺 Otezla Authorised · Amgen Europe B.V.
Follow Apremilast Viatris
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.